Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluticasone Furoate on Methacholine Challenge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* forced expiratory volume in one second (FEV1) greater than or equal to 65% predicted~* methacholine PD20 less than or equal to 400mcg~* no allergen exposure (if atopic) or respiratory infection for at least 4 weeks prior to study start~Exclusion Criteria:~* regular use of inhaled corticosteroid within 4 weeks of study start~* poorly controlled asthma~* current smoker or ex smoker with greater than 10 pack year history~* pregnancy or breast-feeding~* health concern/condition that would preclude participation for safety reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate (Type: EXPERIMENTAL): Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints
- Matching Placebo (Type: PLACEBO_COMPARATOR): Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints

Based on this trial design, predict the completion outcome and termination type (if applicable).